Nurix Enrolls First Patient in Head-to-Head Phase 3 for Bexobrutideg
Nurix Therapeutics enrolled the first participant in DAYBreak CLL-306, a global randomized Phase III trial comparing the BTK degrader bexobrutideg with pirtobrutinib in relapsed or refractory CLL/SLL after progression on a covalent BTK inhibitor….
